Composition for treating helicobacter pylori infection and preparation and application thereof

Abstract

The invention provides a composition for treating helicobacter pylori infection and a preparation and application thereof. The composition is prepared from, by weight, 10-20 parts of rifabutin, 70-120parts of amoxicillin and 2.2-4 parts of (-)-pantoprazole sodium; by adopting the composition, the treatment cycle of a second-line triple therapy can be shortened by 20%, and the treatment cost of apatient is reduced. The invention further provides a capsule used for treating helicobacter pylori infection. The capsule can improve the compliance of the patient, and therefore the rate of eradication for helicobacter pylori is increased.

Description

technical field [0001] The invention belongs to the field of pharmaceutical compositions, in particular to a composition for treating Helicobacter pylori infection and its preparation and application. Background technique [0002] Helicobacter pylori (Hp) is a Gram-negative, microaerophilic bacterium that lives in the stomach and duodenum. It causes mild chronic inflammation of the gastric mucosa and can even lead to gastric and duodenal ulcers and gastric cancer. In my country, more than half of the population has Helicobacter pylori infection, eradicating Helicobacter pylori infection can cure gastritis and duodenal ulcer, and can prevent the occurrence of gastric cancer. The eradication regimen of H. pylori includes standard triple therapy, including proton pump inhibitors, amoxicillin, and clarithromycin. However, due to clarithromycin resistance, the eradication rate of standard triple therapy against H. pylori has dropped significantly to less than 80%. For patients ...

AI Technical Summary

Problems solved by technology

The eradication rate of Helicobacter pylori has been improved by the second-line triple therapy, but the treatment cycle of the second-line triple therapy is longer, and the price of rifabutin is relatively expensive, which increases the treatment cost of patients

And when the second-line triple therapy is taken, each drug needs to be taken separately, and the patient's compliance is poor, thereby reducing the eradication rate of Helicobacter pylori

Images